Loading patent…
AssigneeThe United States of America as represented by the Secretary of Agriculture
InventorsAida E. Rieder, Luis L. Rodriguez, Jason R. Hollister, Sabena Uddowla
Estimating the term…
We have generated novel molecularly marked FMDV A24LL3DYR and A24LL3BPVKV3DYR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3Dpol and 3B proteins. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. The mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A24LL3DYR. Cattle immunized with chemically inactivated vaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine. These vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.
A method of distinguishing between an animal exposed to wild-type Foot and Mouth disease virus (FMDV) and an animal vaccinated with a marker FMDV vaccine, where the marker is a replacement of amino acids His27 and Asn31 of FMDV 3Dpol with the amino acids Tyr and Arg of the 3Dpol of Bovine Rhinovirus type 2 (BRV2), said method comprising:
A method of distinguishing between an animal exposed to wild-type FMDV and an animal vaccinated with a double marker FMDV vaccine, where the double marker is the replacement of amino acids His27 and Asn31 of FMDV 3Dpol with the amino acids Tyr and Arg of the 3Dpol of Bovine Rhinovirus type 2 (BRV2), and the replacement of amino acids RQKP of FMDV 3B with the amino acids PVKV of the 3B of BRV2, said method comprising:
Dependencies are inferred from the claim text.